|
| Status |
Public on Feb 28, 2022 |
| Title |
Combination treatment with BMI1 and MAPK/ERK inhibitors is effective in medulloblastoma |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Epigenetic changes play a key role in the pathogenesis of medulloblastoma (MB), the most common malignant pediatric brain tumor. Here we identify a synergic vulnerability of BMI1High;CHD7Low MB cells to a combination treatment with BMI1 and MAPK/ERK inhibitors and we elucidate the molecular mechanisms underpinning the CHD7-BMI1-MAPK regulatory axis which mediates the anti-tumor effect of these inhibitors in vitro and in vivo, in a pre-clinical mouse model. Enhanced ERK1 and ERK2 phosphorylation activity is found in BMI1High;CHD7Low G4 MB patients, raising the possibility that they could be amenable to a similar therapy.
|
| |
|
| Overall design |
RNA-Seq of MB cells treated with BMI1 and MAPK/ERK inhibitors.
|
| |
|
| Contributor(s) |
Badodi S, Pomella N, Marino S |
| Citation(s) |
35213723 |
| |
| Submission date |
Apr 19, 2021 |
| Last update date |
Jun 08, 2022 |
| Contact name |
Silvia Marino |
| E-mail(s) |
s.marino@qmul.ac.uk
|
| Organization name |
Queen Mary University of London
|
| Street address |
4, Newark St
|
| City |
London |
| State/province |
- |
| ZIP/Postal code |
E12AT |
| Country |
United Kingdom |
| |
|
| Platforms (1) |
| GPL20301 |
Illumina HiSeq 4000 (Homo sapiens) |
|
| Samples (20)
|
|
| Relations |
| BioProject |
PRJNA723029 |
| SRA |
SRP315400 |
Less...
More...